Since Δ133p53α prevents cellular senescence, studying the impact of its mutation in glioblastoma is relevant to determine if it affects the progression and response to treatment of GBM cells and mutant TP53 cancers in general, whether it may be used as a prognostic marker, and represent a potential therapeutic target. The gene discussed is TP53; the disease is glioblastoma.